Jon Jones mocked Daniel Cormier about steroid allegations prior to UFC 214 and now he is facing a drug suspension
Sean M. Haffey/Getty Images
The UFC has confirmed that Jon Jones is being investigated for a failed drug test on the night of his UFC 214 win over Daniel Cormier in which Jones reclaimed the light heavyweight title belt.
According to TMZ, Jones tested positive for Turinabol, an anabolic steroid and that he could be suspended for up to four years.
This would be the second time Jones has tested positive for steroids surrounding a UFC fight, following UFC 200 in 2016 in which he was pulled from the card just three days prior to the event. However, that is only part of the irony of his latest link to steroids.
Prior to UFC 214, Jones mocked Cormier on Twitter about previous steroid allegations, wondering aloud, "wonder what his excuse will be this time."
"Daniel says the only reason I defeated him the first time is because I must have been on steroids," Jones wrote on Twitter in July. "Wonder what his excuse will be this time."
Ouch. As Darren Rovell of ESPN noted, that tweet did not age well.
Daniel says the only reason I defeated him the first time is because I must have been on steroids, wonder what his excuse will be this time pic.twitter.com/HMCFQBoBR4
- Jon Bones Jones (@JonnyBones) July 21, 2017
- I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
- Saudi Arabia wants China to help fund its struggling $500 billion Neom megaproject. Investors may not be too excited.
- One of the world's only 5-star airlines seems to be considering asking business-class passengers to bring their own cutlery
- From terrace to table: 8 Edible plants you can grow in your home
- India fourth largest military spender globally in 2023: SIPRI report
- New study forecasts high chance of record-breaking heat and humidity in India in the coming months
- Gold plunges ₹1,450 to ₹72,200, silver prices dive by ₹2,300
- Strong domestic demand supporting India's growth: Morgan Stanley